chrisvoncsefalvay/vaers-outcomes huggingface dataset:
May 7th, I went to bed and started shivering. I realized the next morning I had a fever and not feeling good. I did the covid test and was positive and went to the med clinic and tested positive. I was prescribed paxlovid for 5 days. I had a horrible taste in mouth and felt very fatigue.
Jerking that lasted approximately 3-5 seconds. Reoccurring every 30 seconds. Subjective fever.
Some fingers and toes swell up after the 2nd dose; Hives on his body after the 2nd dose; Muscular pain in the bones of hand and feet after the 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Some fingers and toes swell up after the 2nd dose), URTICARIA (Hives on his body after the 2nd dose) and MYALGIA (Muscular pain in the bones of hand and feet after the 2nd dose) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Some fingers and toes swell up after the 2nd dose), URTICARIA (Hives on his body after the 2nd dose) and MYALGIA (Muscular pain in the bones of hand and feet after the 2nd dose). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Hives, at an unspecified dose and frequency. At the time of the report, PERIPHERAL SWELLING (Some fingers and toes swell up after the 2nd dose) and MYALGIA (Muscular pain in the bones of hand and feet after the 2nd dose) outcome was unknown and URTICARIA (Hives on his body after the 2nd dose) had resolved.            No concomitant medications were reported.  The first dose was given on dominant upper arm  while as the second dose was given on Non dominant upper arm.    Treatment medication included Steroid shot   Patient stated that he saw his HCP who was going to send him to a Rheumatologist and another specialist.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jul-2021: Follow up received on 15-JUL-2021: Email was added, Outcome of  event hives updated to Recovered.
Headache, wheezing, dizziness, fever, fainted once, eye itching & swelling, mild facial swelling/itching.  Recovered from dizziness & fainting, eye itching but still w/ headache.
Covid 19 positive; Covid 19 positive; This is a spontaneous report received from a contactable reporter(s) (Nurse). The reporter is the patient.  A 32-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Past drug history included: Nsaid, reaction(s): "Known allergies: NSAID", notes: Known allergies: NSAID.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 05Dec2022, outcome "recovering" and all described as "Covid 19 positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (05Dec2022) Positive, notes: Covid 19 positive. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  Clinical course: Patient had not received any other vaccine in four weeks and not received any other medications in two weeks of vaccination. Patient had no covid prior vaccination. Patient had not received any treatment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal relationship between the events drug ineffective, covid-19  and suspect drug BNT162B2 cannot be excluded.
pT DEVELOPED SIGNS AND SYMPTOMS OF hERPES zOSTER OPHTHALMIC BRANCH  OF 5TH NERVE l SIDE 4 days after receiving Zostavax
tested positive for HPV; This spontaneous report was received from a consumer referring to herself, a 30-year-old female patient. The patient's medical history, historical drugs, past drug reactions or allergies, concurrent conditions, and concomitant drugs were not reported.   On an unspecified date in 2006, the patient was vaccinated with Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injection (product circular number: uspi-v501-i-2304r022; strength, dose, route of administration, and anatomical location were not reported) for HPV prevention.  On an unspecified date (reported as "recently" and "a few days ago"), the patient received a pap smear and tested positive for HPV. The patient's healthcare provider relayed to her that it could be HPV types 16, 18, or 45. The patient requested additional testing to find out the exact type of HPV she contracted. The patient contracted it between 2021 and now. The patient was treated for this event and the healthcare provider suggested her to get HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9). The patient had an appointment on 21-APR-2023. The outcome of the event was not recovered. The causal relationship between the event and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) was unknown.
pregnancy; inability to lift after taking the first dose; extreme soreness; nausea; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (pregnancy), HYPOKINESIA (inability to lift after taking the first dose), VACCINATION SITE PAIN (extreme soreness) and NAUSEA (nausea) in a 38-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 17-Oct-2020 and the estimated date of delivery was 24-Jul-2021. On 18-Mar-2021, the patient experienced EXPOSURE DURING PREGNANCY (pregnancy), HYPOKINESIA (inability to lift after taking the first dose), VACCINATION SITE PAIN (extreme soreness) and NAUSEA (nausea). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-first week of the pregnancy.  The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at a dose of UNK dosage form. On 18-Mar-2021, EXPOSURE DURING PREGNANCY (pregnancy) had resolved. At the time of the report, HYPOKINESIA (inability to lift after taking the first dose), VACCINATION SITE PAIN (extreme soreness) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
Back and neck stiffness, trouble swallowing, tongue thickness, facial twitch, and shortness of breathe.
a sinus infection starting; mild fever; This spontaneous case was reported by a health care professional and describes the occurrence of SINUSITIS (a sinus infection starting) and PYREXIA (mild fever) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025120-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, the patient experienced SINUSITIS (a sinus infection starting) and PYREXIA (mild fever). On 02-Feb-2021, PYREXIA (mild fever) had resolved. At the time of the report, SINUSITIS (a sinus infection starting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Relevant concomitant medication was not reported. Treatment information was provided as Advil.  Limited information regarding the events has been provided at this time and a causal relationship cannot be excluded, although it is possible the fever is associated with an unrelated sinus infection as the onset date of both is more than 3 weeks after vaccination.; Sender's Comments: Limited information regarding the events has been provided at this time and a causal relationship cannot be excluded, although it is possible the fever is associated with an unrelated sinus infection as the onset date of both is more than 3 weeks after vaccination
Patient experienced fatigue and muscle aches immediately following the vaccination.  His symptoms became progressively worse as time passed and by the next day he was experiencing chills, fever, tachycardia, shortness of breath, and excruciating chest and upper back pain.  He described the pain in his chest as "stabbing" and also had a small and painful protrusion from his chest wall that was determined to be a lymph node.
Patient received the covid vaccine on 12/21/2020.   c/o new onset fever if 101.1m sore throat, HA, and body ache. Denies chills and cough   Covid test on 12/28/2020 was negative. Restested on 1/5/2021 - result pending.  Not sure if Influenza test was done.
At 2 am I awoke with intense stomach pain. I went into my kitchen to drink a small glass of half and half and take two tums. At some point while in my kitchen I passed out and awoke on the floor. I slid down my kitchen counter/drawers bending and breaking two separate drawer handles causing bruises and long scratches down my back and right elbow. My muscles started contracting, cramping and weak feeling. I broke out in a full sweat and head spinning. My husband had to help me back to bed. This entire episode was quite frightening. Now at 3:14 pm, I?m feeling out of breath, weak muscles and fatigued. My injection site is visibly larger than past flu shots.
severe pain @ time of vax;pain persisted @ site for about 5 days lessening gradually to a dull ache;bruising was evident on 26SEP97; 1 1/2 inch by 1inch;bruising dec very gradually still evident on 17OCT97 22 days later;
Patient received booster dose early, Date of dose #2 was 07/15/21. Patient was not due for booster until 01/15/2021.
Complained of feeling lightheaded about 10 minutes after vaccine administered, Given some water and taken outside to fresh air and felt better after about 10 minutes.
Information has been received from a currently 67 year old female patient reporting on herself. The patient's medical history included: shingles in 2004 (13 years ago), in her back; an unspecified cancer; 2 lumpectomies; brain bleed and stroke. The patient's concomitant medications included: diltiazem hydrochloride (CARDIZEM), linagliptin (GLYXAMBI), gabapentin, metformin, anastrozole and simvastatin (VASTATIN). Her drug reactions/allergies included drug reactions to codeine, acetaminophen + hydrocodone bitartrate (NORCO) and an unspecified derivative of Penicillin. On an unknown date, the patient was vaccinated with ZOSTAVAX in the left arm (dose, strength, route of administration, lot# and expiration date were not provided), for prevention of shingles. On unknown dates the patient experienced shingles (herpes zoster). The patient reported that she had shingles six times since she received the ZOSTAVAX vaccine. After the first episode of shingles experienced 13 years ago, she received the ZOSTAVAX vaccine. She did not remember when she received the vaccine. She reported that she had Shingles on her leg six times after she received the vaccine. The outbreak "looked like a circle" that caused pains when she wore slacks and "it rubed against it". She did not remember when she experienced any of the six outbreaks. She stated that the first time that she had shingles, after receiving the vaccine, on her leg she went to the doctor. The doctor gave her "a cream to put on it". She stated that "the time between breakouts had been shorter" and "this last time it was only a month and a half in between outbreaks". This outbreak began "Saturday", it was really painful and "the pain was not lessening". She did not remember when any of the above mentioned events took place. Additionally, she reported that she was tired from Shingles and that it "zaps" her energy. The patient's outcome and the causality assessment between ZOSTAVAX  and the adverse events was not reported. Additional information has been requested.
Info has been received from a consumer concerning a pt (age and gender not reported) with an unknown medical history who on an unspecified date, was vaccinated with a dose of MMRII (lot unknown). Subsequently, a titer showed antibodies to measles and rubella but not mumps. The pt's status was unknown. There was no product quality complaint involved. Follow-up info was received indicating that the pharmacy intern called on behalf of a physician's office with a general question. It was noted that "the vaccine was not administered by us". Additional info is not expected.
After administering Tdap and Meningococcal vaccines patient stated she felt  dizzy.  Patient had a loss of consciouness and began having seizure like  activity.  After about 15 seconds patient regained consciouness.  Patient  appeared pale and skin was cool and clammy.  Pupils dilated without PERRLA.  Breathing shallow and unlabored.  Patient A&O x3.  Patient had vomiting epidsode  x1. Patient laid on back with legs elevated above head.  Cool compress placed on  forehead. Patient observed for 1 hour and became more alert. Blood pressure,  heart rate, and O2 saturation maintained within normal limits throughout event.  After 1 hour no distress noted and vital signs within normal range. Patient left  ambulatory.  Mother called pediatrician to make appointment for follow up.
headache; fever; numbness in armpit; redness in armpit; swollen lymph node in armpit; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (numbness in armpit), ERYTHEMA (redness in armpit), LYMPHADENOPATHY (swollen lymph node in armpit), HEADACHE (headache) and PYREXIA (fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     Concurrent medical conditions included Thyroid disorder NOS and Cholesterol. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) and ERGOCALCIFEROL, RETINOL PALMITATE (VITAMINS A & D) for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, the patient experienced HYPOAESTHESIA (numbness in armpit), ERYTHEMA (redness in armpit) and LYMPHADENOPATHY (swollen lymph node in armpit). On 17-Mar-2021, the patient experienced HEADACHE (headache) and PYREXIA (fever). On 18-Mar-2021, HEADACHE (headache) and PYREXIA (fever) had resolved. At the time of the report, HYPOAESTHESIA (numbness in armpit), ERYTHEMA (redness in armpit) and LYMPHADENOPATHY (swollen lymph node in armpit) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
When parents returned with infant for 4 mo. Immunizations, they reported that he & his twin became ill with high fever (103-104 degrees F), vomiting & diarrhea within 24 hrs of 2 mo Immunizations. Both were hospitalized and received IV therapy.
Rashes developing on her core/rashes developing around her armpit area/She says the rashes are both sides, left and right; This is a spontaneous report from a contactable consumer or other non-health care professional (patient). A 24-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: not reported, Expiry date: not reported) via an unspecified route of administration, administered in Left Arm on 24Mar2021 12:30 (at the age of 24 years) as DOSE 1, SINGLE for covid-19 immunization. Family medical history relevant adverse event included high blood pressure (mom and dad both have high blood pressure), diabetes (mom has diabetes), and breast cancer (grandmother had breast cancer).No medical history (including any illness at time of vaccination) was reported. No Prior vaccinations (within 4 weeks). Relevant tests were none. No AE following prior vaccinations. The patient other concomitant medications was not reported. No additional vaccines administered on same date of the pfizer suspect was reported. On 10Apr2021, the patient experienced rashes developing on her core, developing around her armpit area and the rashes are both sides, left and right. On 12Apr2021, the patient experienced rashes developing on her core was reported as worsened. The caller was calling about the shot. She says she has a quick question. She asked was it safe for her to get the second shot since she has rashes developing around her core and around her armpit area. No adverse event resulted in emergency room/physician office visit. The outcome of the event was not recovered. No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
fever of 100.4 F; not feeling well (malaise); Chills; Headache; This case was reported by a consumer via call center representative and described the occurrence of fever in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 8th September 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. In September 2020, less than a day after receiving Shingrix, the patient experienced fever, malaise, chills and headache. On an unknown date, the outcome of the fever, malaise, chills and headache were not recovered/not resolved.   It was unknown if the reporter considered the fever, malaise, chills and headache to be related to Shingrix.  Additional details were provided as follows: The patient received vaccine at end of the day and on 9th September 2020 at morning, she woke up and not felt well (malaise) with a headache and chills. The patient had checked temperature, reading was normal, and then going back to sleep for approximately 1.5 hours. After woke up the second time patient checked temperature again and had a fever of 100.4 degree Fahrenheit. The symptoms were not resolved at the time of reporting. The reporter did not consent to health care professional's follow-up, said not necessary. The reporter did not consent to follow-up.
pt w/encopresis which began on 6MAR96 & who was exposed to varicella on 9MAR96 recv vax & on 30JUN97 pt devel chickenpox consisting of mult pustular lesion on the neck & face;also exp fever of 99.8;seen by MD;stiffness & pain in neck;
This spontaneous report was received from a health care professional refers to a currently 41 year old patient of unknown gender. On 29-SEP-2015 the patient was vaccinated with expired dose of VARIVAX (Merck) injection (lot # J009167; expiry: 24-JUL-2015) (dose, route and frequency unspecified). No concomitant medications were reported. The patient had not reported an adverse effect. No additional information was provided. The outcome of medication error was unknown. Additional information has been requested.
Patient was having light headed, dizzy and numbness in hands and lags.  We called 911 and paramedics took patient to hospital
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 17Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 07Apr2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 29Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: BENAZEPRIL, start date: May2022; VITAMIN D NOS, start date: May2022; VITAMIN C [ASCORBIC ACID], start date: May2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 13May2022, outcome "not recovered" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Other medication in 2 weeks was reported as yes.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
3 days later tested positive; got sick right after vaccine; This is a spontaneous report from a contactable consumer (the patient) via the Pfizer-sponsored program.  A female patient of unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 25Jan2021 as a single dose for COVID-19 vaccination. Medical history was not reported. Concomitant medications were not reported.  The patient stated that she got sick right after vaccine - 3 days later she tested positive. She also stated that "all symptoms are gone now."  Her second vaccine is on Monday and she is wondering if its okay to get the second dose on Monday. Lab data included a positive SARS-CoV-2 /COVID-19 test on 28Jan2021. The clinical outcomes of the events illness and COVID-19 were reported as resolved ("all symptoms are gone now") on an unspecified date.  Information on the lot/batch number has been requested.
Itch; Pain; Redness; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itch), PAIN (Pain) and ERYTHEMA (Redness) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2021, the patient experienced PRURITUS (Itch), PAIN (Pain) and ERYTHEMA (Redness). At the time of the report, PRURITUS (Itch), PAIN (Pain) and ERYTHEMA (Redness) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.    Most recent FOLLOW-UP information incorporated above includes: On 17-Apr-2021: Follow-up received included No new Information
Night sweats; Headache; chills; Face blew up; Allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Allergic reaction), NIGHT SWEATS (Night sweats), SWELLING FACE (Face blew up), HEADACHE (Headache) and CHILLS (chills) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced HYPERSENSITIVITY (Allergic reaction) and SWELLING FACE (Face blew up). On 07-Mar-2021, the patient experienced NIGHT SWEATS (Night sweats), HEADACHE (Headache) and CHILLS (chills). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency; PREDNISONE at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. On 06-Mar-2021, HYPERSENSITIVITY (Allergic reaction) and SWELLING FACE (Face blew up) had resolved. On 11-Mar-2021, NIGHT SWEATS (Night sweats), HEADACHE (Headache) and CHILLS (chills) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication provided.
(R) UE cellulitis, warmth/redness. BENADRYL and KEFLEX (if febrile).